1 / 31

RANOLAZINE Dr. Merajuddin shah, MD, DM (Cardiology) Al-Kareem Cardiac Center, Srinagar, Kashmir

RANOLAZINE Dr. Merajuddin shah, MD, DM (Cardiology) Al-Kareem Cardiac Center, Srinagar, Kashmir. METABOLIC MANUPULATION OF ISCHEMIC HEART DISEASE. A NOVEL APPROACH TO TREATMENT -------- Leong Lee , EHJ, 2004. RANOLAZINE A Piperazine Derivative. Chronic Angina.

alethea
Download Presentation

RANOLAZINE Dr. Merajuddin shah, MD, DM (Cardiology) Al-Kareem Cardiac Center, Srinagar, Kashmir

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RANOLAZINEDr. Merajuddin shah, MD, DM (Cardiology)Al-Kareem Cardiac Center, Srinagar, Kashmir

  2. METABOLIC MANUPULATION OF ISCHEMIC HEART DISEASE. A NOVEL APPROACH TO TREATMENT --------Leong Lee , EHJ, 2004

  3. RANOLAZINEA Piperazine Derivative

  4. Chronic Angina • A condition that impairs quality of life and is associated with decreased life expectancy • Current major drug therapies • Nitrates • ß-blockers, • Calcium antagonists All these affect HR and BP

  5. Ranolazine • A drug that reduces angina symptoms, with a mechanism of action different from that of currently available pharmacological therapies. • Do not affect HR & BP. Ranolazine was approved on January 27, 2006, in the United States for use in patients with chronic angina who continue to be symptomatic on ß-blockers, calcium antagonists, or nitrates.

  6. Primary Mechanism of Action: Inhibition of Late Na channel NCX: Sodium-calcium exchange Eur Heart J. 2004;6(suppl I):I3–I7.

  7. Mechanism of action • In ischemia, number of late Na channel (I-Na) increases which leads to calcium overload through Na-Ca exchange. • Ranolazine block these late Na channel, and hence prevent the calcium overload which in turn decreases mechanical dysfunction, abnormal contraction and relaxation, and diastolic tension.

  8. Ranolazine (therapeutically conc.up to 10 µmol/L) selectively inhibit late INa (IC50=5 to 21 µmol/L) • No effect on either the fast sodium current responsible for the upstroke of the action potential (IC50 value of 244 µmol/L for peak INa) or the Na+-H+ and Na+-Ca2+ exchangers. Thus, ranolazine is a relatively selective inhibitor for late INa J Cardiovasc Pharmacol Ther. 2004; 9: S65–S83

  9. Ranolazine & inhibition of various currents • IC50 values for various currents: • Late INa+ 5.9 umol/L • IKr 11.5 umol/L • Late ICa+ 50 umol/L • INa-Ca 91 umol/L • Peak ICa+ 296 umol/L • IKs (17%) 30 umol/L Circulation. 2004;110:904-910

  10. Pharmacokinetics • Food - no effect on Bioavailability The absolute bioavailability - 35% to 50%. Elimination • 80% - by cytochrome P450 (CYP) 3A enzymes • 10-15% by CYP2D6 • 5% Glucuronidation • 5% Excreted unchanged in Urine. • Elimination half-life • 7 hrs - ER formulation

  11. Drug–Drug Interaction • Diltiazem (≥240 mg daily) - ↑ ranolazine plasma levels - 1.5-fold • Ranolazine has no significant effect on diltiazem pharmacokinetics • Verapamil (≥360 mg daily) - 2.3-fold ↑ in ranolazine plasma levels • Ranolazine increases digoxin concentrations 1.4- to 1.6-fold at trough &2-fold at peak plasma levels • Ranolazine is contraindicated in patients on potent and moderately potent CYP3A inhibitors such as ketoconazole, diltiazem, verapamil, macrolide antibiotics, HIV protease inhibitors, and grapefruit juice

  12. Drug–Drug Interaction • Simvastatin Cmax is ↑ by 2-fold after ranolazine; • Simvastatin - no significant effect on ranolazine pharmacokinetics. • In phase II studies of ranolazine with patients on statin drugs, significant increases in creatine kinase, clinical myositis, or elevated liver function tests have not been reported. • No interactions with warfarin • Antiarrhythmic drugs • Class Ia: quinidine • Class III: dofetilide, sotalol • Certain antipsychotics: Thioridazine, ziprasidone

  13. MonotherapyAssessment of RanolazineIn Stable AnginaMARISA • Patients withdrawn from other anti-anginals(N = 191 randomized) • Randomized, double-blind, 4-period crossover • 1-wk treatment periods • Placebo vs 500, 1000, and 1500 mg bid • Exercise tests after each week of treatment • At trough (12 hr after dosing) • At peak (4 hr after dosing) J Am Coll Cardiol 2004;43:1375-82.

  14. 1000 mg bid Monotherapy With Ranolazine Increases Exercise Performance at Trough and Peak MARISA Peak Trough *** *** *** *** ** *** *** *** *** *** *** *** *** *** *** *** *** ** Placebo 500 mg bid N = 175, All/Near Completers population; LS means ± SE. **p< 0.01 vs placebo; ***p < 0.001 vs. placebo 1500 mg bid

  15. Combination Assessment of RanolazineIn Stable AnginaCARISA • Randomization criteria identical to MARISA except for background therapy • Atenolol 50 mg qd (n = 354), or • Amlodipine 5 mg qd (n = 256), or • Diltiazem CD 180 mg qd (n = 213) • Three parallel groups for 12 wk of treatment • Placebo • Ranolazine 750 mg bid • Ranolazine 1000 mg bid • Exercise testing • At trough after 2, 6, and 12 wk of treatment • At peak after 2 and 12 wk of treatment JAMA 2004;291:309-316.

  16. Ranolazine With a Beta- or Calcium Blocker Increases Exercise Times at Trough and Peak CARISA Peak Trough * * ** ** * * *** *** ** * Change from baseline, sec N = 791, ITT/LOCF; LS mean ± SE. *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001 vs placebo. Placebo 750 mg bid 1000 mg bid

  17. Ranolazine Decreases Weekly Angina Attacks and Nitroglycerin ConsumptionCARISA ** *** * *** Angina attacks Nitroglycerin consumption N = 791, ITT/LOCF; LS mean ± SE. *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001 vs placebo

  18. ERICA: Study design Evaluation of Ranolazine In Chronic Angina History of CAD* Stable angina (≥3 angina episodes/week)Amlodipine 10 mg/dayN = 565 Ranolazine extended-release 500 mg bid (1 week) then 1000 mg bidn = 281 Placebon = 284 RandomizedDouble-blind 7 weeks Primary efficacy variable:Angina frequency (weekly average) *≥60% stenosis, previous MI, and/or stress-induced perfusion defect Stone PH et al. J Am Coll Cardiol. 2006;48:566-75.

  19. ERICA: Ranolazine reduces angina frequency and nitrate consumption N = 564 on amlodipine 10 mg/day 6 5 P = 0.028 4 Mean number per week P = 0.014 3 2 1 0 Baseline Week 7 Baseline Week 7 Angina episodes Nitroglycerin use PlacPlaceboebo RRannanolazine 1000 mg bid Stone PH et al. J Am Coll Cardiol. 2006;48:566-75.

  20. ERICA: No significant effect on heart rate or BP N = 564 on amlodipine 10 mg/day; Supine measurement Stone PH et al. J Am Coll Cardiol. 2006;48:566-75.

  21. p = 0.006 p < 0.001 p < 0.04 Ranolazine IR 400 mg tid (1741 ± 1026 ng base/mL) Atenolol 100 mg od Placebo Ranolazine Is at Least as Effective as Atenolol 100 mg DailyRAN080 Time to onset of angina Time to 1-mm ST-depression Exercise duration p < 0.001 p = 0.18 p < 0.001 p < 0.001 p = 0.86 LS mean ± SE, sec p < 0.001 All patients analysis, N = 154.

  22. MERLIN-TIMI 36 • Randomized, placebo controlled tiral. • Subjects: 6560 patients hospitalized with NSTEMI were randomized to ranolazine or placebo, in addition to standard therapy. • Initially ranolazine was given intravenous infusion followed by oral ranolazine. • Median duration of cECG monitoring was 6.8 days. Circulation 2007;116:1647-1652.

  23. MERLIN-TIMI 36: SUMMARY • In more than 6300 patients admitted with NSTEMI, treatment with ranolzine resulted in significantly lower incidence of • ventricular tachycardia, • Supraventricular tachycardia, and • Significant ventricular pauses. Circulation 2007;116:1647-1652.

  24. Summary—Anti-Anginal and Anti-Ischemic Efficacy of Ranolazine • Dose and plasma concentration dependent • Consistent throughout a broad population of chronic angina patients • Not dependent on decreases in blood pressure or heart rate • At least as great asatenolol 100 mg qd (RAN080) • In patients on atenolol or diltiazem at doses considered optimal by their physicians (RAN072)

  25. Safety Common reported adverse events are:- • Dizziness:- 6.2% • Headache:- 5.5% • Constipation:- 4.5% • Nausea:- 4.4% CARISA: the average increase in QTc was 6.1 and 9.2 ms at the ranolazine doses of 750mg and 1000mg twice daily. NO CASES OF TORSADES DE POINTES HAVE BEEN SEEN IN PATIENTS WHO RECEIVED RANOLAZINE IN CLINICAL TRIALS TO DATE

  26. Contraindications • Preexisting QT prolongation • On drugs that prolong QT interval • Hepatic impairment • Patients taking drugs which inhibit CYP3A. • In patients on potent and moderately potent CYP3A inhibitors such as ketoconazole, diltiazem, verapamil, macrolide antibiotics, HIV protease inhibitors, and grapefruit juice.

  27. Indications & Dosage • Treatment of Chronic angina. • Patients who have not achieved an adequate response with other antianginal drug. • It should be used in combination with beta-blockers, amlodipine, or nitrates. • 500mg bid initially, can be increased to 1000 mg bid. • Max. recommended daily dose is 1000 mg bid. • Helps in lowering HbA1c in patients with DM

  28. Summary— Ranolazine Efficacy and Safety • Efficacy demonstrated in 5 double-blind, randomized, placebo-controlled trials • Safe and well tolerated • Adverse events are generally dose dependent and manageable by typical dose titration • No evidence for an adverse effect of ranolazine on survival

  29. Caroza: ANovel Key For Angina

More Related